Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04783415 · ClinicalTrials.gov registry record · Phase 2

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

A Phase 2 study of Mantle Cell Lymphoma, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 2
Development phase
12
Enrollment target
1
Study location

NCT04783415 is a Phase 2 study of Mantle Cell Lymphoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 12 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04783415, a Phase 2 study of Mantle Cell Lymphoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies the effects of acalabrutinib, umbralisib, and ublituximab in treating previously untreated mantle cell lymphoma. Acalabrutinib and umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Ublituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving acalabrutinib and umbralisib with ublituximab may work better in treating mantle cell lymphoma.

Conditions Studied

Mantle Cell Lymphoma

Interventions

  • DRUG Acalabrutinib
  • BIOLOGICAL Ublituximab
  • DRUG Umbralisib

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2021-03-26
Est. Completion 2025-09-20
Phase Phase 2

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04783415

The ClinicalTrials.gov registry entry for NCT04783415 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (88% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Acalabrutinib is the first listed.

NCT04783415 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04783415 about?

NCT04783415 is a clinical study titled "Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma". This phase II trial studies the effects of acalabrutinib, umbralisib, and ublituximab in treating previously untreated mantle cell lymphoma. Acalabrutinib and umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Ublituximab is a monoclonal antibody t...

What is the current status of trial NCT04783415?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-03-26. Estimated completion is 2025-09-20.

What conditions does trial NCT04783415 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma.

What interventions are being tested in trial NCT04783415?

The interventions under investigation include: Acalabrutinib (DRUG), Ublituximab (BIOLOGICAL), Umbralisib (DRUG).

Who is sponsoring clinical trial NCT04783415?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04783415 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mantle Cell Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.